SCHEMBL874845

SCHEMBL874845

Cc1cc(F)ccc1C(=O)Cl

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.47
CES1 P23141 4/20 0.47
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42
CLCN2 P51788 1/20 0.41
MAPK14 Q16539 2/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
KEAP1 Q14145 1/20 0.38
HDAC4 P56524 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
HPGD P15428 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364589 0.83 CES2 (0.47) CES2CES1ALDH1A1ALOX15CLCN2
SCHEMBL2560228 0.83 CES2 (0.50) CES2CES1CLCN2MAPK14MAPK13
SCHEMBL29728646 0.81 KEAP1 (0.53) CES2CES1ALDH1A1CLCN2KEAP1
SCHEMBL30628278 0.81 CES2 (0.48) CES2CES1ALDH1A1KEAP1HDAC4
SCHEMBL1121927 0.81 CES2 (0.48) CES2CES1ALDH1A1KEAP1HDAC4
SCHEMBL543572 0.81 KEAP1 (0.53) CES2CES1ALDH1A1CLCN2KEAP1
SCHEMBL11476969 0.81 CES2 (0.48) CES2CES1CLCN2MAPK14MAPK13
SCHEMBL9834572 0.80 CES2 (0.52) CES2CES1ALDH1A1ALOX15KEAP1
SCHEMBL26019658 0.80 CES2 (0.44) CES2CES1ALDH1A1CLCN2MAPK14
SCHEMBL10971858 0.79 CES2 (0.47) CES2CES1CLCN2MAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119899093-A Synthesis process of 6-fluoro-2-methyl-1-indenone 重庆恩联生物科技有限公司 2025-04-29 CN claimed
CN-111100059-A Structural design and synthesis of novel carbazole oxime ester photoinitiator 北京艾德旺科技发展有限公司 2020-05-05 CN claimed
WO-2025110008-A1 CURABLE COMPOSITION, METHOD FOR PRODUCING PIXEL, FILM, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND PHOTOPOLYMERIZATION INITIATOR 富士フイルム株式会社 2025-05-30 WO disclosed
WO-2025110009-A1 CURABLE COMPOSITION, METHOD FOR PRODUCING PIXEL, FILM, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND PHOTOPOLYMERIZATION INITIATOR 富士フイルム株式会社 2025-05-30 WO disclosed
CN-119899093-A Synthesis process of 6-fluoro-2-methyl-1-indenone 重庆恩联生物科技有限公司 2025-04-29 CN disclosed
US-20240228501-A1 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
WO-2024111393-A1 CURABLE COMPOSITION, METHOD FOR PRODUCING CURED ARTICLE, FILM, OPTICAL ELEMENT, IMAGE SENSOR, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND RADICAL POLYMERIZATION INITIATOR 富士フイルム株式会社 2024-05-30 WO disclosed
EP-4293023-A1 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2023-12-20 EP disclosed
CN-117177974-A Imidazole-containing condensed ring derivative, preparation method and medical application thereof 长春金赛药业有限责任公司 2023-12-05 CN disclosed
CN-111132963-B Compound, composition, cured product, and method for producing cured product 株式会社艾迪科 2023-11-24 CN disclosed
CN-114349714-B Dibenzodiazepine derivative and preparation method and application thereof 华中师范大学 2023-09-29 CN disclosed
EP-1780209-B1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SUCH COMPOUND ADEKA CORP (JP) 2010-03-10 EP disclosed
US-20090004185-A1 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2009-01-01 US disclosed
WO-2008086462-A2 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2008-07-17 WO disclosed
US-20070270522-A1 Oxime Ester Compound and Photopolymerization Initiator Containing Such Compound ADEKA CORPORATION (JP) 2007-11-22 US disclosed
US-20070270522-A1 Oxime Ester Compound and Photopolymerization Initiator Containing Such Compound ADEKA CORPORATION (JP) 2007-11-22 US disclosed
US-20070270522-A1 Oxime Ester Compound and Photopolymerization Initiator Containing Such Compound ADEKA CORPORATION (JP) 2007-11-22 US disclosed
EP-1780209-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SUCH COMPOUND Adeka Corporation (JP) 2007-05-02 EP disclosed
WO-1993014086-A1 SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1993-07-22 WO disclosed
US-4016274-A TRANQUILIZERS AND ANTICONVULSANT AGENTS RHONE-POULENC S.A. (FR) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090004185-A1 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS TCF4, CTNNB1, TCF7 CES2 4605/4885CES1 2720/4885ALDH1A1 2808/4885
US-20240228501-A1 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE KISS1R, CYP3A43, SLC6A11 CES2 2909/4885CES1 2141/4885ALDH1A1 1460/4885
US-20070270522-A1 Oxime Ester Compound and Photopolymerization Initiator Containing Such Compound CBR3, CBR1, SCLY CES2 126/4885CES1 502/4885ALDH1A1 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.